Clinical Trials Browser

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Tumor-Agnostic

Carcinoma

NCT05051735 2026-02-25

PARASTOP

Phase 3 Completed

204 enrolled

Cancer Pain, Neoplasms, Pain

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 1 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

Phase 3 Completed

921 enrolled 43 charts

Genitourinary

Hormone Refractory Prostate Cancer

NCT01013649 2026-02-23

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Phase 3 Completed

546 enrolled 29 charts

Gastrointestinal

Pancreatic Intraductal Neoplasms

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

Breast

HER2-positive Early Breast Cancer

NCT04221945 2026-02-20

KEYNOTE-A18

Phase 3 Completed

1,060 enrolled 30 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04738487 2026-02-20

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Phase 3 Completed

1,264 enrolled 16 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3 Completed

203 enrolled 22 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 2 FDA

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

514 enrolled

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT05894954 2026-02-18

EVANTHEA

Phase 3 Completed

73 enrolled

Lymphoid

Alzheimer Disease, Anomia, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT06235099 2026-02-18

Solar-Recur

Phase 3 Completed

235 enrolled

Genitourinary

Prostatic Neoplasms

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT07413120 2026-02-17

Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery

Phase 3 Completed

40 enrolled

Genitourinary

Adenocarcinoma, Kidney Neoplasms, Prostatic Neoplasms

NCT00400946 2026-02-13

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Phase 3 Completed

800 enrolled 22 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis